Bone Biologics Corp (BBLG): Price and Financial Metrics
BBLG Price/Volume Stats
| Current price | $0.81 | 52-week high | $4.25 |
| Prev. close | $0.83 | 52-week low | $0.57 |
| Day low | $0.79 | Volume | 15,400 |
| Day high | $0.84 | Avg. volume | 181,104 |
| 50-day MA | $0.76 | Dividend yield | N/A |
| 200-day MA | $1.14 | Market Cap | 2.64M |
BBLG Stock Price Chart Interactive Chart >
Bone Biologics Corp (BBLG) Company Bio
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The company is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. Its platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
BBLG Latest News Stream
| Event/Time | News Detail | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BBLG Price Returns
| 1-mo | 21.62% |
| 3-mo | -3.57% |
| 6-mo | -34.15% |
| 1-year | -47.40% |
| 3-year | -99.77% |
| 5-year | N/A |
| YTD | -13.86% |
| 2024 | -79.20% |
| 2023 | -91.02% |
| 2022 | -94.04% |
| 2021 | N/A |
| 2020 | N/A |